The Impact of Tofacitinib on Quality of Life in Patients with Moderate-to-Severe Psoriasis- An Observational Study

被引：0

作者：

Mohta, Alpana ^{[1
]}

Nyati, Asha ^{[2
]}

Ghiya, Bhikam Chand ^{[1
]}

Mehta, Rajesh Dutt ^{[1
]}

Jain, Suresh Kumar ^{[2
]}

机构：

[1] Sardar Patel Med Coll, Dept Dermatol Venereol & Leprol, Bikaner, Rajasthan, India

[2] Govt Med Coll, Dept Dermatol Venereol & Leprol, Kota, Rajasthan, India

来源：

INDIAN JOURNAL OF DERMATOLOGY | 2023年 / 68卷 / 03期

关键词：

Disease severity; PASI; psoriasis; tofacitinib;

D O I：

10.4103/ijd.ijd_697_22

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Global phase III trials have established the effectiveness and the safety profile of 5 and 10 mg twice-daily regimens of Tofacitinib for the management of psoriasis. Aims and Objectives: This study was aimed at assessing the improvement in quality of life in patients suffering from moderate-to-severe psoriasis following 12-week Tofacitinib therapy. Materials and Methods: 50 adults with moderate to severe plaque psoriasis enrolled with informed consent. Tofacitinib was given orally for 12 weeks, as 5 mg or 10 mg twice daily based on weight. Improvement in PASI and DLQI was recorded. Results: We observed a statistically significant improvement in PASI (p-value < 0.001) and DLQI (p-value < 0.001) following Tofacitinib therapy. The 3 domains of DLQI with the most significant improvement were symptoms and feelings (items 1 and 2) (p-value-0.001), daily activities (items 3 and 4) (p-value-0.0001), and treatment (item 10) (p-value-0.0001) Conclusion: Tofacitinib demonstrated a significant improvement in psoriasis disease severity and symptoms with 12 weeks' therapy.

引用

页数：4

共 9 条

[1] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial [J].

Bachelez, Herve ;

van de Kerkhof, Peter C. M. ;

Strohal, Robert ;

Kubanov, Alexey ;

Valenzuela, Fernando ;

Lee, Joo-Heung ;

Yakusevich, Vladimir ;

Chimenti, Sergio ;

Papacharalambous, Jocelyne ;

Proulx, James ;

Gupta, Pankaj ;

Tan, Huaming ;

Tawadrous, Margaret ;

Valdez, Hernan ;

Wolk, Robert .

LANCET, 2015, 386 (9993) :552-561

[2] Review of maintenance of response to psoriasis treatments [J].

Bartos, Simona ;

Hill, Dane ;

Feldman, Steven R. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (04) :293-297

[3] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial [J].

Bissonnette, R. ;

Iversen, L. ;

Sofen, H. ;

Griffiths, C. E. M. ;

Foley, P. ;

Romiti, R. ;

Bachinsky, M. ;

Rottinghaus, S. T. ;

Tan, H. ;

Proulx, J. ;

Valdez, H. ;

Gupta, P. ;

Mallbris, L. ;

Wolk, R. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) :1395-1406

[4] European patient perspectives on the impact of psoriasis:: the EUROPSO patient membership survey [J].

Dubertret, L. ;

Mrowietz, U. ;

Ranki, A. ;

van de Kerkhof, P. C. M. ;

Chimenti, S. ;

Lotti, T. ;

Schaefer, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :729-736

[5] Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis [J].

Feldman, Steven R. ;

Thaci, Diamant ;

Gooderham, Melinda ;

Augustin, Matthias ;

de la Cruz, Claudia ;

Mallbris, Lotus ;

Buonanno, Marjorie ;

Tatulych, Svitlana ;

Kaur, Mandeep ;

Lan, Shuping ;

Valdez, Hernan ;

Mamolo, Carla .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (06) :1162-+

[6] Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study [J].

Krueger, James ;

Clark, James D. ;

Suarez-Farinas, Mayte ;

Fuentes-Duculan, Judilyn ;

Cueto, Inna ;

Wang, Claire Q. ;

Tan, Huaming ;

Wolk, Robert ;

Rottinghaus, Scott T. ;

Whitley, Maryann Z. ;

Valdez, Hernan ;

von Schack, David ;

O'Neil, Shawn P. ;

Reddy, Padmalatha S. ;

Tatulych, Svitlana .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (04) :1079-1090

[7] Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis [J].

Meyer, Debra M. ;

Jesson, Michael I. ;

Li, Xiong ;

Elrick, Mollisa M. ;

Funckes-Shippy, Christie L. ;

Warner, James D. ;

Gross, Cindy J. ;

Dowty, Martin E. ;

Ramaiah, Shashi K. ;

Hirsch, Jeffrey L. ;

Saabye, Matthew J. ;

Barks, Jennifer L. ;

Kishore, Nandini ;

Morris, Dale L. .

JOURNAL OF INFLAMMATION-LONDON, 2010, 7

[8] Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies [J].

Nash, Peter ;

Coates, Laura C. ;

Fleischmann, Roy ;

Papp, Kim A. ;

Jesus Gomez-Reino, Juan ;

Kanik, Keith S. ;

Wang, Cunshan ;

Wu, Joseph ;

Menon, Sujatha ;

Hendrikx, Thijs ;

Ports, William C. .

RHEUMATOLOGY AND THERAPY, 2018, 5 (02) :567-582

[9] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study [J].

Valenzuela, F. ;

Korman, N. J. ;

Bissonnette, R. ;

Bakos, N. ;

Tsai, T. -F. ;

Harper, M. K. ;

Ports, W. C. ;

Tan, H. ;

Tallman, A. ;

Valdez, H. ;

Gardner, A. C. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) :853-862

← 1 →